-
-
Login
A newly published correspondence in The Lancet Diabetes & Endocrinology has now reopened a debate that many healthcare systems believed had largely been settled: does wider CGM adoption always represent good value?
Breaking news! Abbott stripped of sensor's 3D trade mark!
News that Abbott and Dexcom have agreed not to sue each other for patents relating to their CGM tech for another 10 years.
Confirmation that Libre 2 Plus is to replace the Libre 2 sensor.
We welcome news that will sensors can remain in place for MRI and CT scans and X-rays.
